Arcus Biosciences Inc Net Income per Employee (RCUS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Arcus Biosciences Inc   (NYSE: RCUS)
 

Arcus Biosciences Inc Net Income per Employee

RCUS's Quarterly Results, Trends, Rankings, Statistics
Arcus Biosciences Inc recorded a cumulative net loss of $-460 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 162 other companies achieving higher income per employee. While Arcus Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 1859 to 3521.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RCUS Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -765,391 -613,977 -587,354 -567,388 -495,840
RCUS's Total Ranking # 3521 # 1859 # 2442 # #
Seq. Net Income Change - - - - -

RCUS Company Profile >> Back to RCUS Efficiency Comparisons >> Compare RCUS Net Income per Employee to its Competitors

RCUS Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 163
Healthcare Sector # 493
Overall Market # 3521

Net Income per Employee Statistics
High Average Low
$ 132,819 $ -294,989 $ -720,466
(Sep 30 2022)   (Sep 30 2025)




  News about Arcus Biosciences Inc Income per employee

Gilead and Arcus Announce Amended Collaboration and Equity Investment: Accelerating Breakthrough Cancer Therapies

Gilead Sciences, Inc. and Arcus Biosciences, Inc. have recently announced an amendment to their collaboration agreement, along with a significant equity investment by Gilead. The amendment and investment aim to accelerate the growth of the companies joint development programs across multiple indications. In addition, Arcus Biosciences has granted stock options to new employees, further bolstering their commitment to attracting and retaining top talent in the field of oncology.
The collaboration agreement amendment and equity investment of $320 million by Gilead in Arcus common stock at $21.00 per share will pave the way for accelerated growth in the joint development programs between the two companies. This strategic partnership will be instrumental in advancing innovative cancer treatments and combination therapies.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-08T15:11:45+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.